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Background: Post-translational modification of lysine residues of specific proteins by ubiquitin modulates the
degradation, localization, and activity of these target proteins. Here, we identified gains of ubiquitylation sites in
highly conserved regions of human proteins that occurred during human evolution.
Results: We analyzed human ubiquitylation site data and multiple alignments of orthologous mammalian proteins
including those from humans, primates, other placental mammals, opossum, and platypus. In our analysis, we
identified 281 ubiquitylation sites in 252 proteins that first appeared along the human lineage during primate
evolution: one protein had four novel sites; four proteins had three sites each; 18 proteins had two sites each; and
the remaining 229 proteins had one site each. PML, which is involved in neurodevelopment and
neurodegeneration, acquired three sites, two of which have been reported to be involved in the degradation of
PML. Thirteen human proteins, including ERCC2 (also known as XPD) and NBR1, gained human-specific
ubiquitylated lysines after the human-chimpanzee divergence. ERCC2 has a Lys/Gln polymorphism, the derived
(major) allele of which confers enhanced DNA repair capacity and reduced cancer risk compared with the ancestral
(minor) allele. NBR1 and eight other proteins that are involved in the human autophagy protein interaction network
gained a novel ubiquitylation site.
Conclusions: The gain of novel ubiquitylation sites could be involved in the evolution of protein degradation and
other regulatory networks. Although gains of ubiquitylation sites do not necessarily equate to adaptive evolution,
they are useful candidates for molecular functional analyses to identify novel advantageous genetic modifications
and innovative phenotypes acquired during human evolution.
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Ubiquitin is a 76-residue polypeptide that is highly con-
served among eukaryotes. Ubiquitylation of the lysine
residues of substrate proteins targets the ubiquitylated
proteins for degradation by the proteasome [1]. The
ubiquitin-proteasome system is required for targeted
degradation of key regulatory proteins and misfolded
proteins [2]. Ubiquitin and ubiquitin-like proteins, such
as SUMO, ISG15, NEDD8, and ATG8, function as crit-
ical regulators of many cellular processes including sig-
nal transduction, cell-cycle control, and transcription
[1]. Ubiquitylation is known to crosstalk with the phos-
phorylation process to modulate various regulatory* Correspondence: yoonsoo.hahn@gmail.com
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reproduction in any medium, provided the ornetworks [3]. For example, protein kinases can be regu-
lated negatively or positively through ubiquitylation with
or without degradation [3-5].
A large number of genetic modifications have occurred
in the human lineage during primate evolution that
might be responsible for the emergence of human phe-
notypes [6,7]. These genetic modifications include the
generation of novel genes and transcript variants [8,9],
loss of genes [10,11], and acceleration of substitutions in
specific nucleotide and amino acid sequences [12,13].
For example, the FOXP2 protein, which is implicated in
speech and language in humans, acquired two amino
acid substitutions specific to humans after the divergence
of humans and chimpanzees [12]. In contrast to chim-
panzee FOXP2, human FOXP2 differentially regulates
genes involved in central nervous system development
[14]. Introduction of amino acids that are subject toal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 Procedure for identifying gains of ubiquitylation sites
during human evolution. Computational screening and manual
inspection were employed to identify novel gains of ubiquitylation
sites in the human lineage since divergence from the common
ancestor of Euarchontoglires.
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phorylation, during evolution, may be responsible for the
reorganization of regulatory circuits [15]. Some novel
phosphorylation modification sites in human proteins
that originated after the divergence of humans and chim-
panzees have been identified [16].
To assess the impact of PTMs on human proteome
evolution and to identify candidates for evolutionarily
innovative PTM sites, a large amount of PTM data from
human cells is needed. Recent progress in high-
throughput screening by mass spectrometric analysis has
enabled the large-scale characterization of PTM sites in
the human proteome, including phosphorylation sites
[17,18], O-linked β-N-acetylglucosamine modification
sites [19], lysine acetylation sites [20], and ubiquitylation
sites [21-25].
We hypothesize that appearance of novel ubiquityla-
tion sites in proteins along the human lineage during
primate evolution may have modified protein regulatory
networks, potentially resulting in the acquisition of novel
phenotypic traits. To address this possibility, we devel-
oped a bioinformatics method to systematically identify
gains of novel ubiquitylation sites in the human lineage
during primate evolution. As a pilot study, we used ubi-
quitylation data for human proteins reported by Kim
et al. [22] and Wagner et al. [24] as input data and then
analyzed multiple sequence alignments of orthologous
proteins from 37 mammalian species, including humans
and 10 other primates. We then determined when the
ubiquitylated lysine residues of the human proteins first
appeared during primate evolution. Kim et al. and
Wagner et al.’s datasets include lysines modified not
only by ubiquitin, but also by ubiquitin-like proteins
such as SUMO, ISG15, and NEDD8. In this report, we
therefore use the term “ubiquitylation” to indicate both
ubiquitin and ubiquitin-like protein modifications.
Results
Detection and timing of gains of ubiquitylated lysines
during human evolution
We aimed to identify human ubiquitylated lysines located
in highly conserved regions of mammalian proteins that
first appeared along the human lineage during primate
evolution. To do this, a large amount of ubiquitylation site
data and multiple sequence alignments of orthologous
mammalian proteins are required. To assess ubiquityla-
tion sites, one can use databases containing PTM data,
such as UniProt (http://www.uniprot.org) and PhosphoSi-
tePlus (http://www.phosphosite.org) [26], or large-scale
analysis datasets [21-23,25]. In this study, as input data,
we used 23,598 non-redundant human ubiquitylation sites
collected from the datasets of Kim et al. [22] and Wagner
et al. [24], as well as 58,985 mammalian protein align-
ments derived from the ‘multiz46way’ alignment data [27].The overall procedure is illustrated in Figure 1. We fil-
tered out cases where any Euarchontoglires species or
many non-Euarchontoglires mammals had the lysine, or
those where there were multiple copies of the protein in
the human genome or the sequence conservation level
was low. Finally, we identified 281 ubiquitylated lysines in
highly conserved regions of 252 proteins that appeared in
the human lineage during primate evolution. A summary
of our results is presented in Additional file 1 and detailed
alignments are provided in Additional file 2. Of the 252
proteins, one protein (NUP205) acquired four ubiquityla-
tion sites; four proteins (AKAP12, PML, RAD18, and
XRCC5) acquired three sites each; 18 proteins acquired
two sites each; and the remaining 229 proteins acquired
one site each.
The timing of the gain of a ubiquitylated lysine was
determined by finding the branch that enclosed the
earliest shared lysine between humans and other pri-
mates on the mammalian phylogenetic tree. For ex-
ample, the human PML residue Lys 394 (No. 182 in
Additional file 2) is shared with chimpanzee, gorilla, and
orangutan, but not with gibbon and other early-diverged
primates. Hence, this lysine was gained in the ancestor
of the great apes after they diverged from gibbons. In
some cases, the timing could not be determined pre-
cisely due to a lack of informative sequences. For
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in Additional file 1) is shared with the other great apes
(chimpanzee, gorilla, and orangutan) but not with other
primates that diverged earlier. Because the gibbon se-
quence is missing, however, it is not clear whether the
gain of Lys 448 occurred in the ape clade (before the di-
vergence of gibbons) or in the great ape clade (after the
divergence of gibbons). In such ambiguous cases, we in-
ferred that the novel lysine residue was gained in the
smallest clade that included all the species with the
novel lysine residue.
In Figure 2, the distribution of the 281 ubiquitylated
lysines gained in the human lineage is shown in the con-
text of the mammalian phylogenetic tree. The numbers
of lysine gains in each clade of the human lineage were
as follows: humans, 13; humans and chimpanzees, 2;
African great apes, 20; great apes, 6; apes, 32; catarrhines
(Old World monkeys and apes), 56; simians (monkeys
and apes), 116; haplorhines (tarsiers, monkeys, and
apes), 8; and primates, 28. When we surveyed the Uni-
Prot database to determine the molecular function of
the novel ubiquitylation sites, we found that only two
(Lys 400 and Lys 401 of the PML protein) have been
functionally characterized (see below for details). The
potential functional roles of the remaining 279 sites have
yet to be determined.
Human-specific gains of ubiquitylation sites
Of the 281 ubiquitylation sites, 13 sites were human-
specific; that is, these ubiquitylated lysine residues
evolved in humans after the divergence of humans and
chimpanzees. These proteins are CASC5, CIAPIN1,
DSC3, ERCC2, FANCA, KIAA1731, MYO6, NBR1,
NCAPD2, SCO2, SDR42E1, SLX4, and TRMT6 (Table 1).







Figure 2 Timing of the gains of ubiquitylated lysine in the human lin
lineage of the mammalian phylogenetic tree are shown. The number of ga
ancestor of the corresponding clade.was polymorphic in humans, and the derived lysine
allele was the major allele while the ancestral (minor)
allele was shared with chimpanzees and other apes. Mul-
tiple sequence alignments for ERCC2 Lys 701 and NBR1
Lys 435, the two representative human-specific gains,
are shown in Figure 3.
The ERCC2 (excision repair cross-complementing ro-
dent repair deficiency, complementation group 2) protein,
which is also known as XPD, is involved in transcription-
coupled nucleotide excision repair and is implicated in
cancer-prone xeroderma pigmentosum, trichothiodystro-
phy, and Cockayne syndrome [28]. In the highly conserved
C-terminal region of this protein, there is a human-
specific ubiquitylated residue, Lys 701 (equivalent to Lys
751 of UniProt record P18074); other mammals have ei-
ther a glutamine (Q) or an arginine (R) at this position
(Figure 3A and No. 75 in Additional file 2). Interestingly,
this position is polymorphic in humans (Lys/Gln; dbSNP
accession rs13181). The lysine (codon AAG) is the derived
allele while the glutamine (codon CAG) is the ancestral al-
lele that is shared with other apes and monkeys. In the
human population, the derived lysine allele is the major al-
lele with a frequency of 73.285%. Humans with the ances-
tral (minor) glutamine allele have reduced DNA repair
capacity, indicating that the derived lysine allele confers
enhanced DNA repair capacity [29,30]. Hence, the gain of
a lysine at this position is advantageous in humans, al-
though an association between ubiquitylation of the lysine
and enhanced DNA repair capacity remains to be
demonstrated.
The neighbor of BRCA1 gene 1 (NBR1) protein has
been identified as one of the principle cargo receptors
for selective autophagy of ubiquitylated targets [31,32].
Abnormalities in NBR1 have been implicated in a type

















eage. Numbers of gains of ubiquitylated lysine residues in the human
ins is shown on each branch where the lysine residue emerged in the
Table 1 List of proteins with human-specific ubiquitylation sites
Noa Protein IPI accession Modification siteb Positionc Experimentd Title
38 CASC5 IPI00163659.6 QMHVSLKEDENNS 262 Kim cancer susceptibility candidate 5
49 CIAPIN1 IPI00387130 VSVENIKQLLQSA 48 Wagner cytokine induced apoptosis inhibitor 1
67 DSC3 IPI00031549 SGRGVDKEPLNLF 180 Wagner desmocollin 3
75 ERCC2 IPI00442420.2 ESEETLKRIEQIA 701 Kim excision repair cross-complementing rodent repair deficiency,
complementation group 2
82 FANCA IPI00006170.2 GRSLELKGQGNPV 1387 Kim Fanconi anemia, complementation group A
118 KIAA1731 IPI00400986.6 SGTIASKERTLSS 435 Kim KIAA1731
150 MYO6 IPI00844172.1 AQLARQKEEESQQ 993 Kim myosin VI
155 NBR1 IPI00299920.5 ERGAEGKPGVEAG 435 Kim neighbor of BRCA1 gene 1
156 NCAPD2 IPI00299524.1 RGLDGIKELEIGQ 1301 Kim, Wagner non-SMC condensin I complex, subunit D2
214 SCO2 IPI00014458 GLTGSTKQVAQAS 196 Wagner SCO cytochrome oxidase deficient homolog 2 (yeast)
215 SDR42E1 IPI00163504.4 LNRNLIKEVNVRG 96 Kim short chain dehydrogenase/reductase family 42E, member 1
234 SLX4 IPI00291796.2 SDPLEEKKALEIS 1179 Kim SLX4 structure-specific endonuclease subunit homolog
(S. cerevisiae)
259 TRMT6 IPI00099311 HGTFSAKMLSSEP 273 Wagner tRNA methyltransferase 6 homolog (S. cerevisiae)
aThe number corresponds to that in Additional file 1 and in Additional file 2.
bThe ubiquitylated lysine is in bold.
cThe positions are based on the International Protein Index (IPI) records and may differ from those of the UniProt or NCBI Protein records.
dExperimental evidence for modifications: Kim, Kim et al. [22]; Wagner, Wagner et al. [24].
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human-specific ubiquitylated residue, Lys 435, at which
position all the other mammals examined have an glutamic
acid (E) (Figure 3B and No. 155 in Additional file 2). This
novel ubiquitylation site could play a role in the degradation
or molecular function of NBR1. However, it is also possible
that the ubiquitylation of Lys 435 was simply an indication
of NBR1 degradation at the timepoint the experiment was
performed.+
pri Human       EDQLGLSLLSLEQLESEETLKRIEQIAQQL*
pri Chimpanzee  ....................Q.........*
pri Gorilla     ....................Q.........*
pri Orangutan   ....................Q.........*
pri Rhesus      ....................Q.........*
pri Baboon      ....................Q.......SC*
pri Marmoset    ................Q...Q.........*
pri Mouse lemur ..............Q.....R.........*
eua Treeshrew   ....................R.........*
eua Mouse       ..............Q.....Q.........*
eua Rabbit      ....................R.........*
lau Dog         ....................R.........*
lau Cow         ....................R.........*
afr Elephant    ..............Q.....R.........*
xen Armadillo   ..............Q.....R.........*
met Opossum     ..............Q.....R.........*





















Figure 3 Multiple sequence alignments of representative human-spec
which are marked by plus signs (+), and the surrounding regions for ERCC2
highlighted on a black background. The residues that are the same as thos
asterisks (*) denote alignment gaps and stop codons, respectively. Unknow
were removed to save space (see Additional file 2 for complete data). The
mammalian clade to which that species belongs: pri, Primates; eua, Euarch
Metatheria; and pro, Prototheria.Other notable gains of ubiquitylation sites
Of the 281 ubiquitylation sites, 269 sites in 243 human
proteins were acquired along the human lineage during
primate evolution, and are shared with chimpanzees and
other primates (see Figure 4 for representative cases).
The promyelocytic leukemia (PML) protein acquired
three novel ubiquitylation sites in the human lineage:
Lys 394 in the great apes, Lys 400 in the simians, and
Lys 401 in the catarrhines (Figure 4A and Nos. 182–184+
uman      GDSMYSSALSQPGLERGAEGKPGVEAGQEPAEAGERLPGGE
himpanzee ....................E....................
orilla    ....................E....................
rangutan  ....................E.......G............
ibbon     ....................E....................
hesus     ....................E....................
aboon     ....................E....................
armoset   ....................E....................
arsier    ...............QV...E.R..................
reeshrew  ................V...E..I.................
ouse      ....................E..I.S.L..T..R....ER.
abbit     ....................E..I..............A..
og        ....................E..I...-------...AE..
ow        ....................E..I......V.....PL..D
hrew      .................T..EL........I.D.GGST.R.
lephant   ....................E....................
rmadillo  .................T..E...........D.......K
loth      .................T.RE..I.......KD........
possum    .E..............LT.LEQV.K.E......Y...AR..
BR1 Lys 435
ific gains of ubiquitylation sites. Human-specific ubiquitylation sites,
(A) and NBR1 (B) proteins are shown. The gained lysine residues are
e in the human sequence are marked with dots (.). Dashes (−) and
n amino acids are indicated by ‘X’. Some of the non-primate species
three-letter code preceding each species refers to the major
ontoglires; lau, Laurasiatheria; afr, Afrotheria; xen, Xenarthra; met,
A PML Lys 394, 400, 401
+     ++
pri Human       RLQDLSSCITQGKDAAVSKKASPEAASTPRD
pri Chimpanzee  ...............................
pri Gorilla     ...............................
pri Orangutan   ...............................
pri Gibbon      ..H.........T...A..............
pri Rhesus      ............T...XXXXXXXXXXXXXXX
pri Baboon      ............T....A.............
pri Marmoset    .....I......T......Q.R.........
pri Mouse lemur .....I.S...RT..VL.RR.....T..L..
eua Mouse       C...FI.....RIN...AS---.....NQPE
eua Rabbit      .....VARV..AT..IL.RRT..QS....G.
lau Dog         ...E.V....R.T.L..PRR...D..G....
lau Cow         .....V....R.T...L.RR...........
afr Elephant    .....I..T.E.T...LP.R......R...N
afr Rock hyrax  .....V.....RT....PRRPRAA...S..N
C SCARB1 Lys 184
+
pri Human       RAFMNRTVGEIMWGYKDPLVNLINKYFPGMF
pri Chimpanzee  ...............................
pri Gorilla     ...............................
pri Orangutan   ..........V....................
pri Gibbon      ...............................
pri Rhesus      ...............Q...............
pri Baboon      ...............Q...............
pri Marmoset    ...............S.............T.
pri Bushbaby    ...............D.....M...F.....
pri Mouse lemur ........A......D...............
eua Treeshrew   ........A......E....S.......D.L
eua Mouse       ...........L...D..F.HFL.T.L.D.L
eua Rabbit      ...............E...M......L..V.
lau Dog         .......I.......E...IH.....L.N.L
lau Cow         ...............D...IH...Q...NSL
afr Elephant    ...............E...MDF......NLL
afr Tenrec      ...V......FL...D...M.F..Q...NAL
xen Armadillo   ........AD.....E....D.......D.I
met Opossum     ...L...........S...ID.L......LM
pro Platypus    H.......S......E..F.EFL...L...I
B NGDN Lys 33
+
pri Human       LKNLQEQVMAVTAQVKSLTQKVQAGAYPTEK
pri Chimpanzee  ...............................
pri Gorilla     ...............................
pri Orangutan   ...............Q...............
pri Gibbon      ...............Q...............
pri Rhesus      ..........I....Q...............
pri Baboon      ..........I....Q...............
pri Marmoset    ...............Q...K...........
pri Mouse lemur .........T.....QA..K...........
eua Treeshrew   .............H.QA..KR..........
eua Mouse       ..............IQA..T..R..T.S...
eua Rabbit      ...............QA..K..K........
lau Dog         ..............IQA.IK....R......
lau Cow         ...............QT..K....K......
afr Elephant    ...............QA..K...........
xen Armadillo   ...............QA..K...T.......
xen Sloth       ...............QA..K...........
met Opossum     .N......V.....IQA..K.........D.
pro Platypus    ..T............QA.....R...F..K.
F AURKB Lys 211
+
pri Human       VIHRDIKPENLLLGLKGELKIADFGWSVHAP
pri Chimpanzee  ...............................
pri Gorilla     ...............................
pri Orangutan   ...............................
pri Gibbon      ...............................
pri Rhesus      ...............................
pri Baboon      ...............................
pri Marmoset    ...............................
pri Tarsier     ...............................
pri Bushbaby    ...............................
pri Mouse lemur ...............................
eua Treeshrew   ...............Q...............
eua Mouse       ...............Q...............
eua Rabbit      ...............Q...............
lau Dog         ...............Q...............
lau Cow         ...............R...............
lau Shrew       ...............Q...............
afr Elephant    ...............R...............
xen Armadillo   ...............R...............
xen Sloth       ..............PR..V..........TH
met Opossum     ............M..R...............
E ATXN2 Lys 349
+
pri Human       DFVVVQFKDMDSSYAKRDAFTDSAISAKVNG
pri Chimpanzee  ...............................
pri Gorilla     ...............................
pri Orangutan   ...M...........................
pri Gibbon      ...............................
pri Rhesus      ...............................
pri Baboon      ...............................
pri Marmoset    ...............................
pri Tarsier     ...............R...............
pri Bushbaby    ...............R.XXXXXXXXXXXXXX
pri Mouse lemur ...............R.XXXXXXX.......
eua Treeshrew   ...............R...............
eua Mouse       .........T.....R........L......
eua Rabbit      ....A..........R........L..R...
lau Dog         ...............R...............
lau Cow         ...............R...............
lau Shrew       ...M...........R...............
afr Elephant    ...............R...............
afr Tenrec      ...M...........R........L......
xen Armadillo   ...............R...............
xen Sloth       ...............R...............
met Opossum     ............N..R...............
pro Platypus    ...M........N..R...............
D WDR35 Lys 684
+
pri Human       RSLRDSRALIEKVGIKDASQFIEDNPHPRLW
pri Chimpanzee  ...............................
pri Gorilla     ...............................
pri Orangutan   ...............................
pri Gibbon      ...............................
pri Rhesus      ...............................
pri Baboon      ...............................
pri Marmoset    ...............E......Q........
pri Tarsier     ...............E...............
pri Bushbaby    ...............E...............
eua Mouse       ...............E...............
eua Rabbit      ...........M...E...............
lau Dog         ...............E...............
lau Horse       ...............E...............
lau Shrew       ...............E...............
afr Elephant    ...............E...............
xen Armadillo   ...............E..............X
xen Sloth       ...............E...............
met Opossum     ...............D...............
pro Platypus    ...............E...............
Figure 4 Multiple sequence alignments of representative gains of ubiquitylation sites in the human lineage during primate evolution.
Novel ubiquitylation sites (+) and the surrounding regions for PML (A), NGDN (B), SCARB1 (C), WDR35 (D), ATXN2 (E), and AURKB (F) proteins are
presented. See Figure 3 for manipulations and Additional file 2 for complete data.
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http://www.biomedcentral.com/1471-2105/13/306in Additional file 2). These three sites are located within
an eight amino acid range of one another. Two of these
sites, Lys 400 and 401, are modified by RNF4, which is
required for arsenic-induced PML degradation [34]. The
PML gene is often fused with the retinoic acid receptor
α (RARA) gene, which is associated with acute promye-
locytic leukemia [35]. Interestingly, recent studies
revealed that PML has roles in neurodevelopment and
neurodegeneration [36]. It would be very interesting to
investigate if the gain of these three ubiquitylation sites
is associated with the evolution of the human nervous
system.
Human neuroguidin (NGDN) has a ubiquitylated Lys
33 that is shared with chimpanzees and gorillas, while
other early-diverged primates (including orangutans)
and all other mammals examined have a glutamine (Q)
residue at this position (Figure 4B and No. 159 in
Additional file 2). NGDN functions as a translational
regulatory protein by interacting with eukaryotic initi-
ation factor 4E (EIF4E) and cytoplasmic polyadenylation
element binding (CPEB) protein, and is required for the
development of the vertebrate nervous system [37].
The scavenger receptor class B member 1 (SCARB1)
protein is a plasma membrane receptor for high-density
lipoprotein cholesterol (HDL). It mediates cholesterol
transfer to and from HDL [38] and is implicated in
hepatitis C virus entry [39]. In this study, SCARB1 Lys
184 was identified as one of 32 ubiquitylation sites that
were acquired in the apes (Figure 4C and No. 212 in
Additional file 2).
We found that 56 novel ubiquitylation sites in 54 pro-
teins first appeared in the common ancestor of catarrhine
primates. One representative case is WD repeat-containing
protein 35 (WDR35) Lys 684, at which position most other
mammals have a glutamic acid (E) (Figure 4D and No. 273
in Additional file 2). WDR35 has been implicated in spon-
taneous and tumor necrosis factor α-stimulated apoptosis
[40]. WDR35 is required for cilia production; its disruption
results in a range of human ectodermal, visceral, and skel-
etal abnormalities [41,42].
Of the 281 novel human ubiquitylated lysines, 116 in
107 proteins are shared with simians. One example is
ataxin 2 (ATXN2) Lys 349, at which position all the other
mammals examined have an arginine (R) (Figure 4E and
No. 23 in Additional file 2). Expansion of a CAG repeat of
the ATXN2 gene causes spinocerebellar ataxia type 2 [43].
There were 28 human ubiquitylated lysines in 28 pro-
teins that were shared by all primates identified in this
study. For example, aurora kinase B (AURKB) Lys 211
first appeared in primates after their divergence from
the common ancestor of Euarchontoglires and is shared
in all primates examined (Figure 4F and No. 24 in
Additional file 2). Non-primate mammals have either a
glutamine (Q) or an arginine (R) at this position. Aurorakinase B is a component of the chromosomal passenger
complex that functions as a key regulator of mitosis [44]
and is ubiquitylated by a Cullin 3-based E3 ubiquitin lig-
ase during mitosis, which coordinates precise mitotic
progression and completion of cytokinesis [45,46].
Discussion
This report presents the results of a pilot study to sys-
tematically identify gains of novel ubiquitylation sites in
the human lineage since its divergence from the com-
mon ancestor of Euarchontoglires. To achieve this goal,
we analyzed a human ubiquitylation dataset obtained
from large-scale analyses [22,24]. We identified 281
novel ubiquitylation sites in 252 highly conserved pro-
teins that first appeared in the human lineage during pri-
mate evolution, 13 of which are human-specific. We
anticipate that application of our method to analyze the
ubiquitylation data recorded in databases such as Uni-
Prot and PhosphoSitePlus [26] or collected by other
large-scale analyses [21,23,25] will result in identification
of additional instances of gains of novel ubiquitylated
lysines along the human lineage. We also expect that
additional novel ubiquitylation sites will be discovered
when higher quality protein sequences of non-human
mammals become available. The total number of novel
ubiquitylation sites we collected is likely to be an under-
estimate because of the draft quality of non-human
genomes.
In addition to ubiquitylation, lysine residues can be
modified by acetylation, and the cross-talk between
these two lysine modifications is an important regulatory
mechanism [47]. Wagner et al. [24] showed that 1,040
ubiquitylated lysines were also acetylated by comparing
their 11,054 ubiquitylation sites with the 3,428 acetyl-
ation sites reported by Choudhary et al. [20]. To check
whether any novel ubiquitylation sites identified in this
study are also acetylated, we compared our data with
3,948 non-redundant acetylation sites collected from the
UniProt database and Choudhary et al. dataset. We
found that nine ubiquitylated lysines were also acety-
lated. These are DLD Lys 320, FASN Lys 436, FDPS Lys
353, GAPDH Lys 84, LDHA Lys 251, LRPPRC Lys 613,
MCM5 Lys 696, NUP205 Lys 41, and PARP10 Lys 928
(Nos. 63, 85, 89, 96, 125, 128, 135, 170, and 173, respect-
ively, in Additional files 1 and 2). Thus, these nine
newly-gained lysines can be modified not only by ubiqui-
tylation but also by acetylation, suggesting regulatory
cross-talk between lysine ubiquitylation and acetylation.
Although gains of novel ubiquitylation sites do not ne-
cessarily equate to innovative and adaptive changes, they
are useful candidates to evaluate when searching for ad-
vantageous genetic modifications during human evolu-
tion. It is also possible that the modified peptides could
be simply derived from protein molecules destined to be
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time of the experiment. Nevertheless, new ubiquitylation
sites would provide novel target sites to modulate cellu-
lar processes by fine-tuning degradation, intracellular
localization, or the regulatory network. Recently, the ori-
gins and evolution of mammalian and yeast ubiquityla-
tion sites were evaluated by analyzing their eukaryotic
and prokaryotic orthologs [48]. The study revealed that
ubiquitylation sites evolved at a similar rate to other
protein modification sites such as phosphorylation sites,
and that about 70% of 452 mammalian ubiquitylation
sites first appeared during early vertebrate evolution.
Interestingly, some ubiquitylation sites that appeared
during animal evolution have been suggested to be asso-
ciated with development of novel cross-talk pathways
with other modifications such as phosphorylation and
hydroxylation. This report supports our notion that gain
of novel ubiquitylation sites could result in the evolution
of protein regulatory networks.
In the case of ERCC2, the human-specific ubiquity-
lated lysine site is polymorphic in humans. The derived
lysine allele is the major or normal allele, while the an-
cestral (minor) glutamine allele is designated as the mu-
tant, which shows reduced DNA repair capacity; carriers
of this minor allele therefore have an increased cancer
risk [28]. The gain of a ubiquitylated lysine in ERCC2
can be regarded as a concrete example of adaptive gains
identified in this study. Molecular functional analyses
of ubiquitylation sites collected in this study are likely
to reveal more instances of advantageous functional
outcomes.
Interestingly, among the 252 proteins, nine proteins
(DZIP3, FKBP4, KIF23, NBR1, PFKP, PIK3C2A, PRKDC,
SNAP23, and ZWINT) have been found in human
autophagy protein interaction networks [49]. NBR1 has
been proposed to act as one of the principle receptors
for selective autophagosomal degradation of ubiquity-
lated targets [31,32]. Human NBR1 acquired a human-
specific ubiquitylated residue, Lys 435, after the
divergence of humans and chimpanzees. Eight other
human proteins have novel ubiquitylated lysines that
are shared with other primates. These nine proteins
interact with known autophagy proteins such as
N-ethylmaleimide-sensitive factor (NSF) and beclin 1,
autophagy related (BECN1) [49]. It is possible that the
gain of new ubiquitylation sites could provide novel
regulatory interactions for autophagy and/or other pro-
grammed protein degradation processes.
Hagai et al. [48] showed that some non-conserved ubi-
quitylated lysines are compensated for by nearby lysines,
indicating that ubiquitylation sites can move from their
original locations during evolution. In these case, the
exact position of the ubiquitylation site is not critical for
the regulation of the protein and may move over time;this phenomenon has also been observed in studies of
phosphorylation sites [50]. To explore this possibility, we
determined whether an alternative ancestral lysine resi-
due was found in a small window surrounding the novel
ubiquitylated lysine. We analyzed a window of ±5 resi-
dues (from −5 to +5) centered on the novel ubiquitylated
lysine. A highly conserved lysine residue suggests that the
site is a target for ubiquitin/ubiquitin-like protein modifi-
cation. We found that 160 cases of 281 had no conserved
additional lysine within the ±5 residue window, indicating
that the sites that we identified are indeed new ubiquityla-
tion sites. For example, the human-specific lysines of
ERCC2 (Lys 701) and NBR1 (Lys 435) (see Figure 3) were
the only modifiable residues in the window evaluated. An-
other example is NAGLU Lys 59 (Figure 5A), which is
shared by all catarrhine primates. In 91 cases, there are
one or more conserved lysines close to the novel ubiquity-
lated lysine. In these cases, we assumed that the protein
acquired additional ubiquitylation site along the human
lineage. As shown in Figure 5B, there is a highly conserved
lysine in the BIRC2 protein that is ubiquitylated in the
human protein at the −2 position from the novel ubiquity-
lated lysine 448. In the remaining 30 cases, the ancestrally
conserved lysine disappeared as the novel lysine appeared
along the human lineage, suggesting that the ubiquityla-
tion site may have shifted. For example, there is a novel ly-
sine residue (Lys 613) in the LRPPRC protein (Figure 5C)
that first appeared in the common ancestor of apes. At the
−1 position from this novel site, there is an ancestrally
conserved lysine in mammals, including gibbons, but not
in great apes, suggesting that the modified position moved
by a single residue during evolution. This analysis indi-
cates that the majority of the novel ubiquitylation sites
identified in this study, 251 sites out of 281, are new or
additional ubiquitylation targets.
Conclusions
We developed a bioinformatics method to identify novel
ubiquitylation sites that evolved along the human
lineage, resulting in the identification of 281 novel ubi-
quitylation sites. The gain of novel ubiquitylation sites
could result in novel ubiquitin-associated protein regula-
tory interactions. Proteins with a novel ubiquitylation
site are useful candidates in the search for genetic modi-
fications implicated in the emergence of novel pheno-
types during human evolution.
Methods
Datasets and bioinformatics tools
To identify ubiquitylation sites in human proteins, we
used the large-scale analysis datasets of Kim et al. [22]
and Wagner et al. [24]. These researchers utilized a mono-
clonal antibody that recognizes characteristic diglycine-
containing isopeptides following trypsin proteolysis [51].
A NAGLU Lys 59
+
pri Human       RALAAKPGLDT
pri Chimpanzee  ...........
pri Gorilla     ...........
pri Orangutan   ...........
pri Gibbon      ...........
pri Rhesus      ....T......
pri Baboon      ....T......
pri Marmoset    .....E.....
pri Mouse lemur .....ES....
eua Treeshrew   .S...ES....
eua Mouse       ....DES....
eua Rat         ....NES....
eua Squirrel    ....TES....
eua Rabbit      .....ES....
eua Pika        .....ES....
lau Dog         .....ES....
lau Cow         .S..TES....
lau Dolphin     .....ES....
lau Megabat     .....ES....
lau Hedgehog    .....AS....
afr Elephant    .S...ES....
mar Opossum     ....PA.DA..
mar Wallaby     .S..PA..A..
B BIRC2 Lys 448
# +
pri Human      EEEKEKQAEEM
pri Chimpanzee ...........
pri Gorilla    ...........
pri Orangutan  ...........
pri Rhesus     .....R.....
pri Baboon     .....R.....
pri Marmoset   .....R.....
pri Bushbaby   .....R.....
eua Treeshrew  .....R....L
eua Mouse      .....R.T...
eua Rat        .....R.S..T
eua Rabbit     .....R....V
eua Pika       .....R.....
lau Dog        .....R.T...
lau Cat        .....RAT..K
lau Horse      .....R.T...
lau Dolphin    .....R.T..T
lau Alpaca     .....R.T..V
lau Megabat    Q....R.T...
lau Microbat   Q....R.T...
lau Hedgehog   .....R.I..V
afr Elephant   .....R.T..L
xen Sloth      .....R.T...
mar Opossum    K....R.T...
mar Wallaby    K....R.T...
pro Platypus   .....R.N...
C LRPPRC Lys 613
+   #
pri Human       FHQLEKMNVKI
pri Chimpanzee  ...........
pri Gorilla     ...........
pri Orangutan   ...........
pri Gibbon      ....K......
pri Rhesus      ....KE.....
pri Baboon      ....KE.....
pri Marmoset    ....KE..L..
pri Tarsier     ....KE.....
pri Bushbaby    ....KE.....
pri Mouse lemur ....KE.....
eua Treeshrew   ....KE.....
eua Mouse       ....QE....V
eua Rat         ....RE....V
eua Squirrel    ....KE..I..
eua Rabbit      ....KE.....
eua Pika        ....KE.....
lau Dog         ....KE.....
lau Cat         ....KE.....
lau Horse       ....KE.....
lau Cow         ....KE.....
lau Dolphin     ....ME.....
lau Alpaca      ....KE.....
lau Microbat    ....KE.....
lau Hedgehog    ....KE..IN.
lau Shrew       ....KE.....
afr Elephant    ....K...IT.
afr Tenrec      ....KE..L..
xen Sloth       ....KH..I..
mar Opossum     ....K...IA.
pro Platypus    ....K...MV.
Figure 5 Representative cases of new, additional, and shifted ubiquitylation sites. Novel ubiquitylation sites (+) and the surrounding
regions for NAGLU (A), BIRC2 (B), and LRPPRC (C) proteins are presented. Ancestrally conserved lysine residues in the LRPPRC protein that
disappeared in great apes are highlighted on a gray background. Hash symbols (#) indicate ubiquitylated lysines that were experimentally
validated in humans. See Figure 3 for more manipulations.
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center were mapped to human protein sequences to iden-
tify them.
Multiple sequence alignments of the human proteins
and orthologous proteins from other mammalian species
were obtained from the University of California Santa
Cruz (UCSC) Genome Browser Database (http://genome.
ucsc.edu). The ‘CDS FASTA alignment from multiple
alignment’ data, which are derived from the ‘multiz46way’
alignment data [27], were downloaded using the Table
Browser tool of the UCSC Genome Browser. These align-
ment datasets included 36 mammalian species: humans,
nine other primates (chimpanzee, gorilla, orangutan, rhe-
sus macaque, baboon, marmoset, tarsier, bushbaby, and
mouse lemur), eight other Euarchontoglires (treeshrew,
mouse, rat, kangaroo rat, guinea pig, squirrel, rabbit, and
pika), ten Laurasiatheria (dog, cat, horse, cow, dolphin,
alpaca, megabat, microbat, hedgehog, and shrew), three
Afrotheria (elephant, rock hyrax, and tenrec), two
Xenarthra (armadillo and sloth), two Marsupialia (opos-
sum and wallaby), and one Prototheria (platypus) species.
The gibbon protein sequences, which were missing from
the multiz46way data, were predicted from the genome
assembly (nomLeu1) and included in the final alignment,resulting in 37 mammalian species, including 10 non-
human primates. The phylogenetic tree of the 37 mam-
mals used in this study is presented in Additional file 3.
The National Center for Biotechnology Information
(NCBI) Protein database (http://www.ncbi.nlm.nih.gov/
protein) was used to collect protein sequences for some
species. The multiple sequence alignments were gener-
ated using MUSCLE (http://www.drive5.com/muscle).
Computational screening for candidate novel
ubiquitylation sites
The overall procedure employed in this study is presented
in Figure 1. The total number of non-redundant ubiquity-
lation sites used was 23,598 [22,24]. We compared the
peptide sequences containing the ubiquitylation site and
the human proteins in the multiz46way (58,985 sets) to
collect orthologous protein alignments. We found 22,912
human ubiquitylation sites in 6,216 protein alignments.
We analyzed each modification site in the alignment and
discarded cases where non-primate Euarchontoglires spe-
cies (treeshrew, mouse, rat, kangaroo rat, guinea pig,
squirrel, rabbit, and pika) had a lysine residue that was
aligned with the ubiquitylated lysine of the human pro-
teins. A total of 441 sites in 380 protein alignments were
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jected to manual inspection.Manual inspection to select ubiquitylated lysine residues
that appeared along the human lineage
As the final step, we manually examined the 441 candi-
dates to identify plausible cases of gains of ubiquitylation
sites in the human lineage during primate evolution. First,
when multiple copies of the human protein sequence in a
dataset were present in the human genome, the set was
discarded due to uncertainty about the orthology of the
aligned proteins. We also discarded cases showing low se-
quence conservation and cases where many non-primate
proteins had lysine residues that were aligned with the
human ubiquitylated lysine.
Next, we curated each protein dataset. Because the
original multiz46way data set did not include gibbon
sequences, we identified and added the orthologous gib-
bon proteins to the dataset. Proteins with low quality
sequences, with missing amino acids, or derived from
older genome assemblies were replaced with curated
sequences retrieved from the NCBI Protein database or
newly predicted sequences from the most recent assem-
blies. Some protein sequences with low quality regions
or gaps that could not be amended were removed from
the dataset. The multiple sequence alignment was rebuilt
using MUSCLE.
Finally, 281 sites in 252 proteins were collected. We
examined the multiple alignments to estimate the timing
of the gain of the ubiquitylated lysine residue. Possible
functional consequences of the gain of the ubiquitylation
site were assessed by a literature survey. The positions
of the residues noted in this manuscript are derived
from the datasets of Kim et al. [22] and Wagner et al.
[24], which are, in turn, based on the International Pro-
tein Index (IPI) (http://www.ebi.ac.uk/IPI) and may
differ from those of the UniProt or NCBI Protein
databases.Additional files
Additional file 1: List of proteins with novel ubiquitylation sites.
Additional file 2: Detailed alignments of surrounding regions of
novel ubiquitylation sites.
Additional file 3: Phylogenetic tree of the 37 mammals used in this
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